Cited by 63Nanoplatforms for cancer theranosticsDigital Radiography and Breast ImagingAdvanced X-ray and CT Imaging

An all-in-one nanoparticle (AION) contrast agent for breast cancer screening with DEM-CT-MRI-NIRF imaging

Open access
Hsu, Jessica C., Naha, Pratap C., Lau, Kristen C., Chhour, Peter, Hastings, Renee, Moon, Brianna F., Stein, Joel M., Witschey, Walter R. T. +3 more·2018·Nanoscale

Abstract

Conventional X-ray mammography has low diagnostic sensitivity for women with dense breasts. As a result, alternative contrast-enhanced screening tools such as dual energy mammography (DEM), computed tomography (CT), magnetic resonance imaging (MRI), and near-infrared fluorescence (NIRF) imaging are being used or investigated for these women. However, currently available contrast agents are non-ideal, have safety issues, and each imaging technique requires a different contrast agent. We therefore sought to develop a multimodal contrast agent that is functional for each breast imaging modality to simplify the diagnosis process and address the issues of existing contrast agents. Herein, we present a novel "all-in-one" nanoparticle (AION) multimodal imaging probe that has potent DEM, CT, MRI, and NIRF contrast properties and improved biocompatibility. AION were formed by co-encapsulation of a near-infrared fluorophore (DiR), silver sulfide nanoparticles (Ag2S-NP), and iron oxide nanoparticles (IO-NP) in PEGylated micelles. AION showed negligible cytotoxicity, which was in agreement with its minimal silver ion release profiles. AION generated strong contrast with all imaging modalities as demonstrated in phantom imaging. AION allowed in vivo tumor imaging as evidenced by the increase in contrast after injection. This study indicates the potential of AION as an effective multimodal contrast agent for breast cancer diagnosis with a range of imaging methods.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1039/c8nr03741h

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • For achieving multiscale imaging evidence, optical imaging and MSI have been harmonized with clinical imaging.

    “For achieving multiscale imaging evidence, optical imaging and MSI have been harmonized with clinical imaging [141].”

    From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [141]

    The Materials and methods section (In vivo imaging; page unavailable) describes NIRF optical imaging alongside mammography, CT, and MRI in tumor-bearing mice, supporting the integration of optical and other imaging modalities. Our copy does not describe MSI or show that optical imaging and MSI were harmonized with clinical imaging to produce multiscale evidence. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Hsu, J. C., Naha, P. C., Lau, K. C., Chhour, P., Hastings, R., Moon, B. F., Stein, J. M., Witschey, W. R. T., McDonald, E. S., Maidment, A. D. A., & Cormode, D. P.
Affiliations
University of Pennsylvania (US)
Corresponding author
Cormode, David P.
Venue
Nanoscale
Published
2018
Volume
10
Issue
36
Pages
17236-17248
ISSN
  • 2040-3364 (ISSN-L)
  • 2040-3372
OpenAlex
W2889288998
Cited by
63
References
57
Citations by year
2025: 3 · 2024: 4 · 2023: 8 · 2022: 9 · 2021: 11 · 2020: 17 · 2019: 10 · 2018: 1
FWCI
3.90
Type
journal article
Language
en
Open access
Locations
  • Nanoscale (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Division of Graduate Education (1321851)
  • National Institutes of Health (R01 CA227142, R01 HL131557)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Digital Radiography and Breast Imaging
  • Physical Sciences › Engineering › Biomedical Engineering › Advanced X-ray and CT Imaging
Keywords
multimodal contrast agents, breast cancer screening, dual-energy mammography, CT contrast, MRI contrast, near-infrared fluorescence imaging, silver sulfide nanoparticles, iron oxide nanoparticles, silver ion release, cytotoxicity, dense breasts, tumor imaging
MeSH terms
Animals, Breast Neoplasms, Cell Line, Contrast Media, Female, Ferric Compounds, Humans, Magnetic Resonance Imaging, Mammography, Mice, Nude, Neoplasms, Experimental, Tomography, X-Ray Computed, Silver Compounds, Phantoms, Imaging, Nanoparticles, Early Detection of Cancer, Hep G2 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review